Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
5.57
-0.29 (-4.95%)
At close: Nov 20, 2026, 4:00 PM EST
5.60
+0.03 (0.54%)
After-hours: Nov 20, 2026, 7:30 PM EST
Ocular Therapeutix Revenue
Ocular Therapeutix had revenue of $12.87M in the quarter ending September 30, 2026, a decrease of -11.48%. This brings the company's total for the last twelve months to $50.38M, down -9.68% year-over-year. In the year 2025, Ocular Therapeutix had annual revenue of $51.95M, down -18.47%. That makes Ocular Therapeutix the 27,981st largest company in the world by revenue and 3,770th in the United States.
Revenue (ttm)
$50.38M
Revenue Growth
-9.68%
P/S Ratio
24.32
Revenue / Employee
$155,028
Employees
325
Market Cap
1.23B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.95M | -11.77M | -18.47% |
| Dec 31, 2024 | 63.72M | 5.28M | 9.03% |
| Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
| Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
| Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
| Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
| Dec 31, 2019 | 4.23M | 2.24M | 112.41% |
| Dec 31, 2018 | 1.99M | 67.00K | 3.48% |
| Dec 31, 2017 | 1.92M | 36.00K | 1.91% |
| Dec 31, 2016 | 1.89M | 137.00K | 7.83% |
| Dec 31, 2015 | 1.75M | 978.00K | 126.68% |
| Dec 31, 2014 | 772.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 10.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 413.37M |
| Novavax | 411.65M |
| Generate Biomedicines | 21.07M |
| Taysha Gene Therapies | 5.49M |
| Absci | 1.49M |
| Silence Therapeutics | 456.00K |
OCUL News
- 2 days ago - Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Ocular Therapeutix Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 11 days ago - Ocular Therapeutix price target raised to $28 from $25 at H.C. Wainwright - TheFly
- 13 days ago - Ocular Therapeutix Earnings Call Transcript: Q3 2026 - Transcripts
- 13 days ago - Ocular Therapeutix Earnings release: Q3 2026 - Filings
- 13 days ago - Ocular Therapeutix Quarterly report: Q3 2026 - Filings
- 13 days ago - Ocular Therapeutix reports Q3 EPS (42c), consensus (35c) - TheFly
- 13 days ago - Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire